Navigation Links
New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir

ta showed that patient self-adjustment of insulin treatment with Levemir® was as safe and effective when compared to dosing that was adjusted by physicians according to standard-of-care. The patients who self-adjusted their dosage achieved a level of diabetes control that was comparable to that of patients receiving physician-driven adjustments. Minimal weight change was observed in both trial arms.1

The findings on weight gain are consistent with previous studies of Levemir®, the first insulin to show less weight gain versus other basal insulins in 12 of 12 controlled clinical trials*. Weight gain is a common side effect of insulin therapy, which is a concern given that 80 percent of people with type 2 diabetes are overweight or obese.

About the Study (Abstract #197-OR):
The new data presented at ADA were from a six-month analysis of 5,604 Type 2 diabetes patients, in a mainly primary care settings, and predominantly treated with Levemir® once-daily, as an add-on therapy to any other glucose-lowering regimens, or as replacement of a previous basal insulin. Patients were randomized to either the “303 Algorithm” [self adjusting their Levemir® dose every three days based on fasting plasma glucose (FPG)] or “Standard-of-Care” (Levemir® dose was physician-adjusted according to standard-of-care) treatment groups.
The study showed that the average A1c, an indicator of long-term blood glucose control, decreased from 8.5 percent at baseline to 7.9 percent at 26 weeks for the 303 Algorithm group, and from 8.5 percent to 8.0 for Standard-of-Care group (p=0.001). Compared to baseline, FPG values decreased by 34 and 21 mg/dL for 303 Algorithm and Standard-of-Care groups, respectively (p<0.0001).
At 26 weeks, 88 percent of all patients remained on once-daily Levemir® therapy. In a subset of insulin-naïve patients who added Levemir® to their standard-of-care therapy, well ove
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:10/30/2014)... -- Nektar Therapeutics (Nasdaq: NKTR ) will announce ... 30, 2014 on Thursday, November 6, 2014, after the ... president and chief executive officer, will host a conference ... Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... of the conference call can be accessed through a ...
(Date:10/30/2014)... BOTHELL, Wash. , Oct. 30, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... Company,s third quarter 2014 financial results will be released ... will host a conference call and live webcast at ...
(Date:10/30/2014)... 30, 2014 Extensiv ... Aufbau von Kuhmilchverträglichkeit     Kuhmilchproteinallergie (KMPA) ... Säuglingen und Kleinkindern. Der bisher übliche Umgang ... der Babys bzw. deren stillenden Mütter Milchproteine ... sich bei einer beträchtlichen Anzahl von Kindern ...
Breaking Medicine Technology:Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 3
... Oct. 26 Gentiva Health Services, Inc. (Nasdaq: GTIV ... services, announced today that it will present at the Oppenheimer ... ET on Tuesday, November 2, 2010 and the Credit Suisse ... (3:30 p.m. ET) on Wednesday, November 10, 2010. ...
... RICHMOND, Va., Oct. 26 Insmed Inc. (Nasdaq: ... it will host a conference call on Wednesday, November ... results for the third quarter 2010.  Insmed intends to ... market opens on November 3rd. To participate ...
Cached Medicine Technology:Gentiva® Health Services to Present at the Oppenheimer and Credit Suisse Healthcare Conferences 2Gentiva® Health Services to Present at the Oppenheimer and Credit Suisse Healthcare Conferences 3Insmed to Host Third Quarter 2010 Conference Call 2
(Date:10/30/2014)... Horse Sense & Sensitivity ... special needs individuals in the Jacksonville area, will be ... from 10-2:00 p.m. at Bailey's Farm (2202 Bishop Estates ... public and is designed to raise awareness and funds ... HSS Round-Up is free. Ticket purchases will be required ...
(Date:10/30/2014)... 30, 2014 REV'D Provision Co. announced ... available through a unique service called, The Feed ... empower the everyday athlete. The Feed has taken the ... created a system to pass that information on to ... is now available on The Feed!” says REV’D® marketing ...
(Date:10/30/2014)... October 30, 2014 Victory Healthcare, ... its 2014 third quarter infection rates and patient ... infection rates of only two percent or less, ... scores exceeding 98 percent. , “We are delighted ... included rising satisfaction scores,” said Robert Helms, chairman ...
(Date:10/30/2014)... 29, 2014 (HealthDay News) -- Scientists who used stem ... say their breakthrough could provide a new way to ... diseases. The team used human pluripotent stem cells ... the body -- to grow the functional miniature stomachs, ... a major cause of ulcers and stomach cancer. ...
(Date:10/30/2014)... Oct. 29, 2014 (HealthDay News) -- Many U.S. ... campus, even though tanning increases the risk for ... among young adults, particularly white women, so colleges ... health, the researchers said. "Public health efforts ... population awareness of the harms that indoor tanning ...
Breaking Medicine News(10 mins):Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2
... WASHINGTON, Sept. 23 Speaker Nancy Pelosi delivered opening remarks ... Day Summit" this morning in the Capitol Visitor,s Center. Below are ... , "Thank you, Chairwoman Barbara Lee for your leadership ... , , "Essential to the CBC,s efforts ...
... , SAN FRANCISCO, Sept. 23 ... Convention to be held at the Santa Clara Marriot from ... Founded in 1998, FA is an international fellowship of individuals ... addiction. For many people who use food as a drug, ...
... release pills and capsules that show a tendency in the ... in a faster and potentially unsafe manner in patients who ... until proven safe with testing in people. That,s the ... issue of ACS, Molecular Pharmaceutics , a bi-monthly journal. ...
... , , WASHINGTON, Sept. 23 ... Americans are reporting stress attributed to financial concerns despite rising unemployment ... (APA). , , In a poll surveying ... 2009, 75 percent of adults reported that the economy caused stress ...
... , , PRINCETON, N.J., Sept. ... buy and carry condoms, the makers of Trojan(R) Brand Condoms recently ... and discreet plastic case. The new product, which is designed to ... the checkout counters of many food, drug and convenience retail locations, ...
... , NORTHRIDGE, Calif., Sept. 23 Today, Nature ... Your Greatness(TM) contest. Nature Made is the nation,s best-selling ... drug, mass and club channels. The company celebrates the inherent ... year, challenged Americans to submit their personal stories of greatness ...
Cached Medicine News:Health News:Pelosi Remarks at the Congressional Black Caucus Foundation's Annual Legislative Conference 2Health News:Pelosi Remarks at the Congressional Black Caucus Foundation's Annual Legislative Conference 3Health News:Food Addicts Convention Draws 800 Members from 31 States, 5 Nations Around the World 2Health News:Food Addicts Convention Draws 800 Members from 31 States, 5 Nations Around the World 3Health News:Interview Alert: At Anniversary of Financial Meltdown, Psychologists Notice Downward Trends in Economic Stress 2Health News:Makers of Trojan(R) Brand Condoms Introduce Trojan 2GO(R), a Unique, Portable, Protective and Discreet Packaging for Condoms 2Health News:Makers of Trojan(R) Brand Condoms Introduce Trojan 2GO(R), a Unique, Portable, Protective and Discreet Packaging for Condoms 3Health News:Makers of Trojan(R) Brand Condoms Introduce Trojan 2GO(R), a Unique, Portable, Protective and Discreet Packaging for Condoms 4Health News:National 'Greatness' Contest Winners Announced 2Health News:National 'Greatness' Contest Winners Announced 3
... Titanium Cranial Fixation Systems incorporate a ... requested by surgeons and surgical staff. ... may be either shaped on the ... a pre-measured, cut, bent and shaped ...
Specially designed combination of demineralized bone fibers and demineralized bone cubes that are both osteoinductive and osteoconductive. Packs well into bone defects. Eliminates the need to mix can...
... matrix and conductive cancellous chips. ... be free of foreign matter. ... is 125 to 1000 . ... 1 - 8 mm. 5:3 ...
Demineralized cortical fibers and cancellous chips....
Medicine Products: